CytoSorbents Announces Virtual Annual Meeting

MONMOUTH JUNCTION, N.J., May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, will host its Virtual Annual Meeting on Tuesday, June 2, 2020 at 10:00 AM EDT.  Stockholders of record will be able to virtually join and submit questions, and those that have not yet voted will be able to vote their shares electronically at the meeting.

To participate in the Virtual Annual Meeting, stockholders will need the 16-digit control number included on the "Important Notice Regarding the Availability of Proxy Materials" proxy card or voting instruction form. If you join through your brokerage firm's website and do not have your control number, you can gain access to the meeting by logging into your brokerage firm's website 30 minutes prior to the meeting start, selecting the shareholder communications mailbox to link through to the meeting, and the control number will automatically populate. 

The Annual Meeting webcast will begin promptly at 10:00 AM Eastern Time. We encourage stockholders to access the Annual Meeting 30 minutes prior to the start time, to allow ample time for the check-in procedures. Technicians will be ready to assist with any technical difficulties you may have accessing the virtual Annual Meeting.  A phone number where you can obtain technical assistance will be made available on the Stockholder Meeting Link 30 minutes prior to the Annual Meeting.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® has been used in more than 80,000 human treatments to date.  CytoSorb has received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.  CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL™, HemoDefend™, VetResQ™, K⁺ontrol™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. 

Please Click to Follow Us on Facebook and Twitter

CytoSorbents Contact: 
Amy Vogel 
(732) 398-5394 
[email protected]

Investor Relations Contact: 
Jeremy Feffer 
LifeSci Advisors 
917-749-1494 
[email protected]

Public Relations Contact: 
Eric Kim 
Rubenstein Public Relations 
212-805-3052 
[email protected] 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-announces-virtual-annual-meeting-301066229.html

SOURCE CytoSorbents Corporation